Recent ECDC data show that despite progress in prevention and control efforts, the hepatitis B and hepatitis C viruses (HBV and HCV) continue to pose significant public health challenges in the European Union and European Economic Area (EU/EEA).
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis C. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis C.
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis B. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis B.
Viral hepatitis is an inflammation of the liver caused by a virus. The most common hepatitis viruses in Europe are types A, B, and C (commonly referred to as HAV, HBV and HCV).
You may already know about PrEP - the pill one takes to reduce the risk of acquiring HIV. But did you know there is also PEP - the post-exposure prophylaxis - that is used after one may have been exposed to the HIV virus.
This evidence brief summarises key issues and priorities for action in Europe and Central Asia on HIV testing. It is largely based on data collected in 2021 by the European Centre for Disease Prevention and Control (ECDC) to monitor implementation of the 2004 Dublin Declaration.
This evidence brief summarises key issues and priorities for action in Europe and Central Asia on PrEP. It is largely based on data collected between March and September 2021 by the European Centre for Disease Prevention and Control (ECDC) to monitor implementation of the 2004 Dublin Declaration.